NovoCure (NAS:NVCR) Net Margin %

: -29.05% (As of Dec. 2022)

View and export this data going back to 2015. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. NovoCure's Net Income for the three months ended in Dec. 2022 was $-37.3 Mil. NovoCure's Revenue for the three months ended in Dec. 2022 was $128.4 Mil. Therefore, NovoCure's net margin for the quarter that ended in Dec. 2022 was -29.05%.

The historical rank and industry rank for NovoCure's Net Margin % or its related term are showing as below:

NVCR' s Net Margin % Range Over the Past 10 Years
Min: -746.89 Med: -30.23 Max: 4.01
Current: -17.2

NVCR's Net Margin % is ranked worse than
59.95% of 819 companies
in the Medical Devices & Instruments industry
Industry Median: 0.12 vs NVCR: -17.20

NovoCure Net Margin % Historical Data

The historical data trend for NovoCure's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Margin %

-25.62

-2.06

4.01

-10.91

-17.20

NovoCure Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Net Margin %																-19.86	-3.38	-17.04	-20.29	-29.05

Competitive Comparison

For the Medical Instruments & Supplies subindustry, NovoCure's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

NovoCure Net Margin % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Net Margin % distribution charts can be found below:

* The bar in red indicates where NovoCure's Net Margin % falls in comparison to its industry or sector. The grey bar indicates the Net Margin %'s extreme value range as defined by GuruFocus.

NovoCure Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

NovoCure's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-92.534	/	537.84
	=	-17.20 %

NovoCure's Net Margin for the quarter that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (Q: Dec. 2022 )	/	Revenue (Q: Dec. 2022 )
	=	-37.303	/	128.429
	=	-29.05 %

NovoCure (NAS:NVCR) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

NovoCure Net Margin % Related Terms

Thank you for viewing the detailed overview of NovoCure's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

NovoCure (NAS:NVCR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (NAS:NVCR) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

NVCR:Mexico 038:Germany

Address

Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF

Website

https://www.novocure.com

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.

Executives

Arye Barak Ben	officer: General Counsel	TOPAZ BUILDING, 4TH FLOOR, MATAM CENTER, PO BOX 15022, SH'AR HACARMEL, HAIFA L3 31905
William Patrick Burke	officer: Chief Human Resources Officer	195 COMMERCE WAY, PORTSMOUTH NH 03801
Timothy J Scannell	director	2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Ashley Cordova	officer: Chief Financial Officer	20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355
Frank X Leonard	officer: Chief Development Officer	20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355
Uri Weinberg	officer: Chief Science Officer	NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355
Ely Benaim	officer: Chief Medical Officer	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Jeryl L Hilleman	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Pritesh Shah	officer: Chief Commercial Officer	C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355
Sherilyn S Mccoy	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
David Hung	director	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Martin J. Madden	director	C/O MICROBOT MEDICAL INC., 175 DERBY STREET 27/1, HINGHAM MA 02043
Steve Futrell	10 percent owner	780 THIRD AVENUE, 46TH FLOOR, NEW YORK NY 10017
Frances Janis	10 percent owner	780 THIRD AVENUE, 46TH FLOOR, NEW YORK NY 10017
Michael D Granoff	10 percent owner	780 THIRD AVENUE, 46TH FLOOR, NEW YORK NY 10017